VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic ...

Beacon Therapeutics has exercised its option agreement to license Abeona Therapeutics’ patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases ...

Alice T. Epitropoulos, MD, FACS, outlines her approach to managing evaporative dry eye. This includes diagnosing meibomian gland dysfunction, using thermal pulsation to clear gland blockages, and ...

Key Takeaways Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for neovascular AMD, diabetic macular edema, and other ocular ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Patients are much more comfortable with AI use behind the scenes as well, the results showed. For administrative tasks, respondents said they approve of AI use in scheduling and reminders (35%), ...

Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies. Vakharia insights from the ...

Sanaregen Vision Therapeutics has made an announcement inviting prospective investors to reserve shares of stock ownership. This comes as the company prepares to launch its equity crowdfunding ...

Key Takeaways Krystal Biotech's phase 3 trial, IOLITE, evaluates KB803 for corneal abrasions in DEB patients, targeting the disease at a molecular level. The trial involves 16 patients, aged six ...

Stuart Therapeutics, Inc. announced the initial results of its phase 3 clinical trial evaluating ST-100 (vezocolmitide) ophthalmic solution for treating dry eye disease. The topline results enumerated ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...